Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
AssigneeCelcuity Inc.
InventorsBrian Francis SULLIVAN, Lance Gavin LAING
Life of this patent
Estimating the term…
Abstract
Provided are methods of treating cancer in a human subject. The method includes selecting a subject in need of treatment of cancer; administering to the subject a therapeutically effective amount of gedatolisib at least once a week for a period of three weeks; discontinuing administration of gedatolisib for a period of one week; and resuming administration of gedatolisib at least once a week following the period of discontinuation. The administration for at least a period of three weeks and discontinued administration for at least a period of one week constitutes a cycle, where the cycle is repeated for at least two cycles.
Claims28
A method of treating breast cancer in a human subject, said method comprising:
- selecting a human subject in need of treatment of breast cancer;
- administering to the human subject (i) hormonal treatment;
- and (ii) a therapeutically effective amount of gedatolisib, or a pharmaceutically acceptable salt, solvate, or ester thereof, once a week for a period of three weeks;
- discontinuing administration of gedatolisib, or pharmaceutically acceptable salt, solvate, or ester thereof, for a period of one week;
- and
- resuming administration of gedatolisib, or pharmaceutically acceptable salt, solvate, or ester thereof, once a week following the period of discontinuation,
- wherein the administration for a period of three weeks and discontinued administration for a period of one week constitutes a cycle, wherein the cycle is repeated for at least two cycles.
A method of treating breast cancer in a human subject, the method comprising:
- administering to a human subject with breast cancer (i) an estrogen receptor antagonist;
- and (ii) gedatolisib, or a pharmaceutically acceptable salt, solvate, or ester thereof, at a dosage of 180 mg/week, once a week for a period of three weeks
- discontinuing administration of gedatolisib, or pharmaceutically acceptable salt, solvate, or ester thereof, for a period of one week;
- and
- resuming administration of gedatolisib, or pharmaceutically acceptable salt, solvate, or ester thereof, once a week following the period of discontinuation,
- wherein the administration for a period of three weeks and discontinued administration for a period of one week constitutes a cycle, wherein the cycle is repeated for at least two cycles.
Dependencies are inferred from the claim text.